Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid.

The soluble fraction of brain samples from patients with Alzheimer's disease contains highly biologically active amyloid-β seeds. In this study, we sought to assess the potency of soluble amyloid-β seeds derived from the brain and cerebrospinal fluid. Soluble Alzheimer's disease brain extracts were serially diluted and then injected into the hippocampus of young, APP transgenic mice. Eight months later, seeded amyloid-β deposition was evident even when the hippocampus received subattomole amounts of brain-derived amyloid-β. In contrast, cerebrospinal fluid from patients with Alzheimer's disease, which contained more than 10-fold higher levels of amyloid-β peptide than the most concentrated soluble brain extracts, did not induce detectable seeding activity in vivo. Similarly, cerebrospinal fluid from aged APP-transgenic donor mice failed to induce cerebral amyloid-β deposition. In comparison to the soluble brain fraction, cerebrospinal fluid largely lacked N-terminally truncated amyloid-β species and exhibited smaller amyloid-β-positive particles, features that may contribute to the lack of in vivo seeding by cerebrospinal fluid. Interestingly, the same cerebrospinal fluid showed at least some seeding activity in an in vitro assay. The present results indicate that the biological seeding activity of soluble amyloid-β species is orders of magnitude greater in brain extracts than in the cerebrospinal fluid.

[1]  E. Scarpini,et al.  Detection of misfolded Aβ oligomers for sensitive biochemical diagnosis of Alzheimer's disease. , 2014, Cell reports.

[2]  Clemens F. Kaminski,et al.  Direct Observation of Heterogeneous Amyloid Fibril Growth Kinetics via Two-Color Super-Resolution Microscopy , 2013, Nano letters.

[3]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[4]  M. Staufenbiel,et al.  Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.

[5]  K. Blennow,et al.  Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease , 2013, PloS one.

[6]  David A Bennett,et al.  Brain amyloid-β oligomers in ageing and Alzheimer's disease. , 2013, Brain : a journal of neurology.

[7]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[8]  R. Sperling,et al.  New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF , 2013, Alzheimer's & Dementia.

[9]  D. Holtzman,et al.  Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls , 2013, Annals of neurology.

[10]  Henrik Zetterberg,et al.  Fluid biomarkers in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[11]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[12]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[13]  Nick C Fox,et al.  Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[14]  Mathias Jucker,et al.  The Amyloid State of Proteins in Human Diseases , 2012, Cell.

[15]  M. Staufenbiel,et al.  Soluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition , 2011, The Journal of Neuroscience.

[16]  C. Dobson,et al.  In situ measurements of the formation and morphology of intracellular β-amyloid fibrils by super-resolution fluorescence imaging. , 2011, Journal of the American Chemical Society.

[17]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[18]  Frank Baumann,et al.  Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis , 2010, Science.

[19]  D. Selkoe,et al.  The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. , 2010, Brain : a journal of neurology.

[20]  K. Blennow,et al.  Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease , 2010, Acta Neuropathologica.

[21]  K. Imahori,et al.  Isolation and Characterization of Patient-derived, Toxic, High Mass Amyloid β-Protein (Aβ) Assembly from Alzheimer Disease Brains* , 2009, The Journal of Biological Chemistry.

[22]  C. Glabe,et al.  Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.

[23]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[24]  Henrik Zetterberg,et al.  Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.

[25]  A. Giese,et al.  Cell-free formation of misfolded prion protein with authentic prion infectivity , 2006, Proceedings of the National Academy of Sciences.

[26]  D. Walsh,et al.  Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.

[27]  M. Staufenbiel,et al.  Amyloid-Associated Neuron Loss and Gliogenesis in the Neocortex of Amyloid Precursor Protein Transgenic Mice , 2002, The Journal of Neuroscience.

[28]  A. Roher,et al.  Evidence for Seeding of β-Amyloid by Intracerebral Infusion of Alzheimer Brain Extracts in β-Amyloid Precursor Protein-Transgenic Mice , 2000, The Journal of Neuroscience.

[29]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Wisniewski,et al.  Cerebrospinal fluid inhibits Alzheimer β‐amyloid fibril formation in vitro , 1993, Annals of neurology.

[31]  D. Teplow,et al.  Cerebrospinal Fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization. , 2010, Journal of Alzheimer's disease : JAD.

[32]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[33]  D. Teplow Preparation of amyloid beta-protein for structural and functional studies. , 2006, Methods in enzymology.

[34]  D. Teplow Preparation of amyloid β-protein for structural and functional studies , 2006 .

[35]  P. Scheltens,et al.  Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. , 2005, Clinical chemistry.

[36]  A. Roher,et al.  Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.